2025. Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s660. DOI:https://doi.org/10.25251/1g590e41.